Stuka Paul purchased $18K of NSPR

Stuka Paul purchased 20,000 shares of InspireMD, Inc. (NSPR) at $0.88 on 2026-05-27.

Original reporting
SEC EDGAR · Stuka Paul
Published May 29, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NSPR
Bullish
medium confidence
Mentioned
$NSPR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NSPRBullishLow
01

Why it matters

The disclosed buy may slightly improve near-term sentiment, but without accompanying guidance, trial, regulatory, or financial updates, it is unlikely to materially re-rate the stock.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is not a standalone catalyst.

03

What to watch

No 10b5-1 plan is cited; however, the article does not clarify whether the director’s prior trading pattern suggests a signal or a one-off action.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed 2026-05-29 for a 2026-05-27 purchase

Background

The article is an SEC Form 4 insider transaction disclosure (director open-market purchase) for InspireMD, Inc.

Company-level read

Ticker impact

$NSPRBullishMedium confidence
Context

InspireMD director Stuka Paul bought 20,000 shares in an open-market transaction at $0.8750 on 2026-05-27, disclosed via Form 4.

Expected impact

Likely limited/short-lived impact; any move would be sentiment-driven rather than thesis-changing.

Evidence & confidence

The filing provides a discrete ownership change and price/size, but no new company-specific operational or financial information.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity/compensation-related or driven by diversification rather than a near-term outlook change.

Key entities

  • InspireMD, Inc.

    Company whose director insider purchase is disclosed on SEC Form 4.

  • Stuka Paul

    Director who purchased 20,000 shares of NSPR at $0.8750/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRHighAI 8/10

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR